Get the Stockscreener App
7.07
0.71%
0.05
After Hours:
7.07
Bicycle Therapeutics Plc Adr stock is traded at $7.07, with a volume of 370.90K.
It is up +0.71% in the last 24 hours and down -2.08% over the past month.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
See More
Previous Close:
$7.02
Open:
$7.08
24h Volume:
370.90K
Relative Volume:
1.36
Market Cap:
$352.57M
Revenue:
$36.90M
Net Income/Loss:
$-166.28M
P/E Ratio:
-2.1489
EPS:
-3.29
Net Cash Flow:
$-203.53M
1W Performance:
-1.26%
1M Performance:
-2.08%
6M Performance:
-32.02%
1Y Performance:
-74.05%
1-Day Range:
$6.86
$7.319
1-Week Range:
$6.835
$7.3226
52-Week Range:
$6.10
$28.67
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
Name
Bicycle Therapeutics Plc Adr
Sector
Industry
Phone
011441223261503
Address
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
7.07 | 485.15M | 36.90M | -166.28M | -203.53M | -3.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Equal-Weight |
| Sep-06-24 | Initiated | RBC Capital Mkts | Outperform |
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-11-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Aug-31-22 | Initiated | Cowen | Outperform |
| Jul-28-22 | Initiated | Barclays | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Apr-13-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Apr-07-22 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-14-22 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | SVB Leerink | Outperform |
| Dec-09-21 | Initiated | Needham | Buy |
| Sep-30-21 | Initiated | B. Riley Securities | Buy |
| Apr-20-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-12-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-20 | Initiated | Oppenheimer | Outperform |
| Apr-17-20 | Initiated | H.C. Wainwright | Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Sep-11-19 | Upgrade | Goldman | Neutral → Buy |
| Jun-17-19 | Initiated | Canaccord Genuity | Buy |
| Jun-17-19 | Initiated | Goldman | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
| Jun-17-19 | Initiated | Piper Jaffray | Overweight |
View All
Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News
Cubist Systematic Strategies LLC Sells 2,650 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - Defense World
Bicycle Therapeutics appoints oncology veterans Dansey and Hoppenot to board - Investing.com
Caption Management LLC Sells 81,517 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Armistice Capital LLC Has $22.69 Million Holdings in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
DAFNA Capital Management LLC Sells 40,000 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR $BCYC Stock Holdings Cut by Tybourne Capital Management HK Ltd. - MarketBeat
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025 - GlobeNewswire Inc.
Candriam S.C.A. Acquires 117,331 Shares of Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Analysts’ Weekly Ratings Updates for Bicycle Therapeutics (BCYC) - Defense World
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress - Investing.com
Bicycle Therapeutics’ SWOT analysis: stock faces pivotal phase amid clinical progress By Investing.com - Investing.com South Africa
Bicycle Therapeutics (NASDAQ:BCYC) Given New $13.00 Price Target at Morgan Stanley - Defense World
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results - Placera.se
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock? - MSN
Rice Biotech Launch Pad adds TPG Life Sciences’ Carolyn Ng to board - Investing.com
Coursera (NYSE:COUR) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Teacher Retirement System of Texas - Defense World
Principal Financial Group Inc. Boosts Stock Position in Schneider National, Inc. (NYSE:SNDR) - Defense World
Principal Financial Group Inc. Purchases 1,695 Shares of Monarch Casino & Resort, Inc. (NASDAQ:MCRI) - Defense World
Teacher Retirement System of Texas Has $465,000 Stake in Beam Therapeutics Inc. (NASDAQ:BEAM) - Defense World
Teacher Retirement System of Texas Sells 1,266 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
William Blair Brokers Decrease Earnings Estimates for TLX - Defense World
Principal Financial Group Inc. Purchases 5,315 Shares of Aaron’s Holdings Company, Inc. (NYSE:PRG) - Defense World
First Northwest Bancorp (FNWB) Expected to Announce Quarterly Earnings on Thursday - Defense World
Principal Financial Group Inc. Raises Stake in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) - Defense World
The Bank of Nova Scotia (TSE:BNS) Receives Average Rating of “Hold” from Analysts - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up – Should You Buy? - Defense World
Market Update: Bicycle Therapeutics Plc ADR (BCYC) Sees Negative Movement, Closing at 7.40 - DWinneX
Bicycle Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com South Africa
How should investors view Bicycle Therapeutics Plc ADR (BCYC)? - uspostnews.com
PBF Energy Inc [PBF] Records 50-Day SMA of $19.79 - knoxdaily.com
UGI Corp [UGI] Records 200-Day SMA of $27.63 - knoxdaily.com
Cellebrite DI Ltd [NASDAQ: CLBT] Sees Increase in Stock Value - knoxdaily.com
Bicycle Therapeutics Plc ADR [BCYC] Shares Fall -0.69 % on Wednesday - knoxdaily.com
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading - MSN
Bicycle Therapeutics Plc ADR Inc. (BCYC) Price Performance: The Role of Supply and Demand - investchronicle.com
Fastenal Co (FAST) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock By Investing.com - Investing.com India
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 By Investing.com - Investing.com South Africa
Bicycle therapeutics COO Alistair Milnes sells $16,850 in stock By Investing.com - Investing.com South Africa
Bicycle Therapeutics chief product officer sells shares worth $5,735 - Investing.com
Bicycle Therapeutics CEO Lee Kevin sells shares worth $43,612 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 - Investing.com
Bicycle therapeutics CFO Alethia Young sells $1,724 in stock - Investing.com
Bicycle therapeutics CTO Michael Skynner sells shares worth $14,292 - Investing.com
Bicycle Therapeutics chief accounting officer sells shares worth $2,499 By Investing.com - Investing.com UK
Bicycle Therapeutics stock hits 52-week low at $8.6 amid downturn By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances By Investing.com - Investing.com South Africa
Bicycle Therapeutics reshuffles leadership, aims for oncology advances - Investing.com India
Bicycle Therapeutics stock hits 52-week low at $8.98 By Investing.com - Investing.com South Africa
Bicycle Therapeutics Plc Adr Stock (BCYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):